Rho site logo

Federal Research Projects

As our Principal Investigators will tell you, we are motivated by discovery and results to improve health, extend life, and enhance quality of life. We achieve this by helping our federal and academic clients run clinical trials and epidemiologic studies. We also guide them through complex FDA regulations and submissions to get new products and devices approved, and clinical standard manuscripts published.

We support studies that seek new treatments for diseases that affect the immune system. We aid the search for safer and more effective medical countermeasures, including pandemic influenza vaccinations for adults and anthrax vaccinations for our most vulnerable populations. We support pioneering research that involves organ and stem cell transplantation. We explore effective options for treating dental and craniofacial pain. And we evaluate interventions to reduce the devastating effects of food allergies and asthma on children.

As the DAIT SACCC, Rho is at the forefront of providing robust, full-service support critical to the design, development, execution, monitoring, and analysis of clinical research studies sponsored by DAIT.  Rho supports 9 consortia that comprise 3 disease area groups: Asthma & Allergic Diseases, Autoimmune Diseases, and Transplantation.

As part of the BARDA MCM CSN ID/IQ multiple award task order contract pool, Rho competes for full-service task orders to design and conduct clinical studies needed to develop medical countermeasures—drugs, vaccines, and diagnostic tests—that help protect public health against bioterrorism, pandemic influenza, and other health emergencies.

Through the CROMS contract, Rho provides full-service and tailored clinical research support services to clinical studies on oral, dental, and craniofacial diseases that are supported by the NIDCR’s Intramural and Extramural programs.

Rho participated in the Learning Early About Peanut allergy (LEAP) study and follow-up study to determine whether early introduction of peanut in the diets of high-risk children could lead to a reduction in peanut allergy at age 5.

Rho is participating in a phase 2 trial that is assessing the safety and immunogenicity of the Panblok H7 influenza vaccine (at 3 different dosages) with an adjuvant.

Rho serves as the Regulatory Affairs Consultant Services contractor for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biotechnology Products and Biologics (CREATE Bio) program.

Rho participated in a study that evaluated the safety, efficacy, and durability of disease stabilization in patients with relapsing-remitting multiple sclerosis that were given an experimental treatment of high-dose immunosuppressive therapy with transplantation of their own blood-forming stem cells.

Rho is participating in a phase 2 trial that is assessing the safety and immunogenicity of the BioThrax anthrax vaccine administered to adults aged 66 and older compared with subjects aged 18 through 50 years.

The CREW is a consortium of 12 birth cohorts comprising 6,000+ research participants established to examine early-life risk factors for asthma and allergic disease. Rho’s role is to collaborate closely with the University of Wisconsin-Madison leaders of the CREW consortium to act as the coordinating center for the project, assisting with administrative coordination and study process standardization.

Rho participated in a study that compared graft and patient survival outcomes between pediatric heart transplant recipients with and without alloantibodies.

Rho serves as the Statistical and Data Coordinating Center for the 12-center pediatric liver transplant iWITH study, which seeks to find out if it is safe to slowly reduce and then stop immunosuppression taken by children who have received liver transplants. The study is being led by the University of California at San Francisco.

 

Rho serves as the Data Coordinating Center for the 3-clinical site SOPPRANO study, which seeks to evaluate the efficacy of extended-release propranolol compared to placebo for reducing pain in patients with temporomandibular disorder (TMD). The study is being led by the University of North Carolina at Chapel Hill.